ABIVAX vs Amneal Pharmaceuticals

ABIVAX (ABVX), health care, and Amneal Pharmaceuticals (AMRX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Amneal Pharmaceuticals is worth $7.4B on the stock market and ABIVAX $7.2B: Amneal Pharmaceuticals is valued at 2% more. Over the past year ABIVAX's share price has moved -26.5% and Amneal Pharmaceuticals's +83.5%.

Key facts

ABIVAX market value
$7.2B
Amneal Pharmaceuticals market value
$7.4B
Amneal Pharmaceuticals P/E
52.8
Amneal Pharmaceuticals revenue
$3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

ABIVAX vs Amneal Pharmaceuticals: every measure side by side
Measure ABIVAX Amneal Pharmaceuticals
SectorHealth CareHealth Care
Country France United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.2Blower$7.4Bhigher
Revenue—$3B
Earnings-$372.9Mlower$72.1Mhigher
Employees98lower8,700higher
Total assets$648.3Mlower$3.7Bhigher
Valuation
P/E—52.8
P/S—2.4
P/B—13.8
Dividend yield—0.00%
Profitability
Operating margin—13.1%
Balance sheet
Net assets$505.1Mhigher-$70.8Mlower
Total liabilities$143.3Mlower$3.7Bhigher
Total debt—$2.6B
Cash on hand$573.3Mhigher$282Mlower
Price change
Today-1.81%lower-0.52%higher
1 year-26.5%lower+83.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Amneal Pharmaceuticals only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns ABVX

Further comparisons

Learn

Questions and answers

Which is bigger, ABIVAX or Amneal Pharmaceuticals?

By market value, Amneal Pharmaceuticals is the larger: $7.4B against $7.2B for ABIVAX.

Which superinvestors own both ABIVAX and Amneal Pharmaceuticals?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold ABIVAX and 0 hold Amneal Pharmaceuticals.

Cite this page

Funkfolio, “ABIVAX vs Amneal Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/abvx-vs-amrx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.